Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Nonsense-Mediated mRNA Decay (NMD) Inhibition and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SMG1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMG1 Recombinant Protein (Kinase Domain / Full Length) High purity (>90%), Endotoxin controlled. Sequence Verified. Suitable for in vitro kinase profiling. |
View SMG1 Products |
| Gene Delivery | SMG1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and NMD reporter assays. |
View SMG1 Products |
| Benchmark Ab | Anti-SMG1 Recombinant Antibody Recombinant positive control for Western Blot, IP, and intracellular flow cytometry. |
View SMG1 Products |
| Validator | SMG1 siRNA Set For knockdown verification and functional validation of NMD pathway inhibition. |
View SMG1 Products |
| Related Target A | UPF1 The primary downstream substrate of SMG1 kinase. Phosphorylation of UPF1 is the direct biomarker of SMG1 activity. |
View UPF1 Products |
| Related Target B | ATR PI3K-related kinase (PIKK) family member. Critical homolog for off-target selectivity screening. |
View ATR Products |
| Related Target C | ATM PI3K-related kinase (PIKK) family member. Key counter-screening target to prevent DNA damage response toxicity. |
View ATM Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PIKK Family Off-Target Profiling | Homolog panel (ATR, ATM, mTOR, DNA-PKcs) proteins strictly verified by mass spectrometry and sequence analysis |
| Substrate Phosphorylation Assay | High-purity recombinant UPF1 substrate available with guaranteed purity >95% for robust kinase assays |
| Lack of Controls | Sequence-verified recombinant anti-SMG1 antibodies included as positive control benchmarks |
| False Positives in Small Molecule Screens | Validated siRNA sets included for orthogonal target knockdown verification |
Live SMG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SMG1 therapeutics is intensifying, with major players shifting focus from traditional oncology targets to nonsense-mediated mRNA decay (NMD) inhibition as a novel immunotherapeutic modality. SMG1 is a member of the phosphatidylinositol 3-kinase-related kinase (PIKK) family and plays a central role in NMD, a surveillance pathway that degrades transcripts with premature translation termination codons. Inhibiting SMG1 leads to the accumulation of PTC-containing mRNAs, translating into truncated proteins that act as tumor-specific neoantigens. As first-generation small molecule inhibitors reach preclinical and early clinical evaluation, the next wave of R&D is targeting selective SMG1 inhibitors to synergize with immune checkpoint blockade therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Eisai (H3 Biomedicine), Academic Spin-offs | Solid Tumors, MSI-H Cancers, Hematological Malignancies | Selectivity Assay (Need Mutant vs WT Proteins, and PIKK Family Panel) |
| RNAi / Antisense | Preclinical Biotechs | Genetic Diseases (PTC-readthrough), Rare Diseases | Target Knockdown Validation (Need High-titer Lentivirus & siRNA) |
| Combination Therapies (w/ PD-1) | Translational Oncology Consortia | Immune-cold Tumors, Refractory Solid Tumors | Biomarker Assays (Need UPF1 Phosphorylation Detection Tools) |